The company is listed in the Swiss Performance Index (SPI ... European champion in generic and biosimilar medicines.” Sandoz made sales of $4.8 billion in the first half of the year, up 8% ...

Sandoz's 2024 revenue grew 4%, with a core EBITDA margin of 20.1%, generating $622M in free cash flow, or $1.45/share. Click ...

Sandoz, a Swiss generic drugs group, has signed a $2bn revolving credit facility, wrapping up a sweeping capital markets exercise that saw the company print Swiss franc and euro bonds. The revolver ...

After completing its spin-off from Novartis in October 2023, Sandoz has been busy launching new products and simplifying its business. Whilst generics made up the bulk of the Swiss company’s $10 ...

Edouard Marcel Sandoz was a Swiss animalier sculptor. His best known works are depictions of foxes, rabbits, and cats, in bronze, ceramic, and stone. Though he also produced watercolors of landscapes ...

(Bloomberg) — Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 billion). The Sandoz Family Foundation, through the ...

The Swiss pharma group said last October that it was looking into the future of Sandoz, which could include ... saying merely that a decision would be made "at the latest" by the end of 2022.

2023 was an exceptional year for Sandoz, Europe's largest generic and biosimilar medicines company and one of the pharmaceutical industry's most storied brands. Sandoz' USD 11.2bn spin-off from ...